Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 537-546

  Tsai, Ming Hsien ^a   Lin, Keh Ming ^a   Hsiao, Mei Chun ^b   Shen, Winston W ^c   Lu, Mong Liang ^c   Tang, Hwa Sheng ^d   Fang, Chun Kai ^e   Wu, Chi Shin ^f   Lu, Shao Chun ^a   Liu, Shu Chih ^a   Chen, Chun Yu ^a   Liu, Yu Li ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CYP2C19; CYP2D6; CYP3A4; Escitalopram; Major depression; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESCITALOPRAM; LORAZEPAM; NORCITALOPRAM; ZOLPIDEM;

ADULT; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; CLINICAL GLOBAL IMPRESSION SCALE; DNA PURIFICATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; EVENING DOSAGE; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC POLYMORPHISM; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE DOSAGE; GENE FREQUENCY; HUMANS; MALE; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 77950350248     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.168     Document Type: Article

References (41)

1. Robinson OJ, Sahakian BJ: Recurrence in major depressive disorder: a neurocognitive perspective. Psychol. Med. 38, 315-318 (2008).
2. Baldwin DS, Reines EH, Guiton C, Weiller E: Escitalopram therapy for major depression and anxiety disorders. Ann. Pharmacother. 41, 1583-1592 (2007).
3. Rao N: The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet. 46, 281-290 (2007).
4. Kobayashi K, Chiba K, Yagi T et al.: Identifcation of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther. 280, 927-933 (1997). (Pubitemid 27171357) (Pubitemid 27171357)
5. von Moltke LL, Greenblatt DJ, Giancarlo GM et al.: Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 29, 1102-1109 (2001).
6. Reis M, Lundmark J, Bengtsson F: Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther. Drug Monit. 25, 183-191 (2003).
7. Yu BN, Chen GL, He N et al.: Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab. Dispos. 31, 1255-1259 (2003).
8. Maron E, Tammiste A, Kallassalu K et al.: Serotonin transporter promoter region polymorphisms do not infuence treatment response to escitalopram in patients with major depression. Eur. Neuropsychopharmacol 19, 451-456 (2009).
9. Tian C, Gregersen PK, Seldin MF: Accounting for ancestry: population substructure and genome-wide association studies. Hum. Mol. Genet. 17, R143-R150 (2008).
10. Sheng HH, Zeng AP, Zhu WX et al.: Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population. Acta Pharmacol. Sin. 28, 279-286 (2007).
11. Garcia-Barcelo M, Chow LY, Chiu HF et al.: Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 46, 18-23 (2000).
12. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
13. Ismail R, Teh LK, Amir J, Alwi Z, Lopez CG: Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia. J. Clin. Pharm. Ther. 28, 279-284 (2003).
14. Ji L, Pan S, Marti-Jaun J et al.: Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem. 48, 983-988 (2002).
15. Johansson I, Oscarson M, Yue QY et al.: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459 (1994).
16. Solus JF, Arietta BJ, Harris JR et al.: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5, 895-931 (2004).
17. Gaedigk A, Bradford LD, Alander SW, Leeder JS: CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos. 34, 563-569 (2006).
18. Zhou H-H: Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series 1244, 51-61 (2002).
19. Horai Y, Nakano M, Ishizaki T et al.: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46, 198-207 (1989).
20. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006).
21. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E: Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83, 322-327 (2008).
22. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
23. Dai D, Tang J, Rose R et al.: Identifcation of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831 (2001).
24. Qiu XY, Jiao Z, Zhang M et al.: Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol. 64, 1069-1084 (2008).
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, The Fourth Edition, Text-Revised. American Psychiatric Publisher, Washington, DC, USA (2000).
26. Hamilton M: Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6, 278-296 (1967).
27. Uhr M, Tontsch A, Namendorf C et al.: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57, 203-209 (2008).
28. Hamilton M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56-62 (1960).
29. Seretti A, Cusin C, Lattuada E et al.: Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol. Psychiatry 4, 280-283 (1999). (Pubitemid 29292180) (Pubitemid 29292180)
30. McGahuey CA, Gelenberg AJ, Laukes CA et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther. 26, 25-40 (2000).
31. Kristoffersen L, Bugge A, Lundanes E, Slordal L: Simultaneous determination of citalopram, fuoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fuorescence detection. J. Chromatogr. B. Biomed. Sci. Appl. 734, 229-246 (1999).
32. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50, 31-34 (2000).
33. Bodin L, Beaune PH, Loriot MA: Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J. Biomed. Biotechnol. 2005, 248-253 (2005).
34. Bertilsson L, Lou YQ, Du YL et al.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51, 388-397 (1992).
35. Steimer W, Zopf K, von Amelunxen S et al.: Allele-specifc change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50, 1623-1633 (2004).
36. Hinrichs JW, Loovers HM, Scholten B, van der Weide J: Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur. J. Clin. Pharmacol. 64, 979-986 (2008).
37. Steen VM, Andreassen OA, Daly AK et al.: Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5, 215-223 (1995).
38. Wigginton JE, Cutler DJ, Abecasis GR: A note on exact tests of Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 76, 887-893 (2005).
39. Schenk PW, van Fessem MA, Verploegh-van Rij S et al.: Association of graded allele-specifc changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol. Psychiatry 13, 597-605 (2008).
40. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73, 13-22 (1986).
41. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).